Loading...

Abbvie Inc (NYSE:ABBV)

151.44 USD +2.33 USD ( +1.56% )
Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist

Intrinsic Value

The intrinsic value of one ABBV stock under the Base Case scenario is 132.48 USD. Compared to the current market price of 151.44 USD, Abbvie Inc is Overvalued by 13%.

The Intrinsic Value is calculated as the average of the two valuation methods:

Overvaluation 13%
Intrinsic Value
Price
Bear Case
Base Case
Bull Case

Fundamental Analysis

ABBV Profitability Score
Profitability Due Diligence

Abbvie Inc's profitability score is 74/100. The higher the profitability score, the more profitable the company is.

Declining ROIC
Positive Revenue Growth Forecast
Positive ROIC
Positive 1-Year Revenue Growth
74/100
Profitability
Score

Abbvie Inc's profitability score is 74/100. The higher the profitability score, the more profitable the company is.

ABBV Solvency Score
Solvency Due Diligence

Abbvie Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

High D/E
Positive Net Debt
Average Interest Coverage
Short-Term Liabilities
32/100
Solvency
Score

Abbvie Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Wall Street
Price Targets

ABBV Price Targets
Price Targets made by Wall Street

12-month price targets for ABBV stock made by Wall Street professionals. The average price target is 168.02 USD with a low forecast of 116.15 USD and a high forecast of 210 USD.

Lowest
Price Target
116.15 USD
23% Downside
Average
Price Target
168.02 USD
11% Upside
Highest
Price Target
210 USD
39% Upside

12-month price targets for ABBV stock made by Wall Street professionals. The average price target is 168.02 USD with a low forecast of 116.15 USD and a high forecast of 210 USD.

Competitors

Competitors Valuation
Abbvie Inc Competitors

Shareholder Return

Stock Performance
ABBV Price Statistics

ABBV Market
1 Week -1% +0%
6 Months +30% -14%
1 Year +35% -6%
3 Years +121% +41%
1M 1M
-3%
6M 6M
+30%
1Y 1Y
+35%
3Y 3Y
+121%
5Y 5Y
+182%

Company Profile

Abbvie Inc

Country

United States of America

Industry

Biotechnology

Market Cap

263B USD

Dividend Yield

3.67%

Description

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products include Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The firm's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.

Contact

ILLINOIS
North Chicago
1 N Waukegan Rd
+18479327900.0
https://www.abbvie.com/

IPO

2013-01-02

Employees

50 000

Officers

Chairman & CEO
Mr. Richard A. Gonzalez
Vice Chairman & Pres
Dr. Michael E. Severino M.D.
Vice Chairman of Fin. & Commercial Operations and CFO
Mr. Robert A. Michael
Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.
Ms. Laura J. Schumacher
Exec. VP & Chief Commercial Officer
Mr. Jeffrey Ryan Stewart
Exec. VP of Operations
Dr. Azita Saleki-Gerhardt Ph.D.
Show More
Sr. VP of R&D and Chief Scientific Officer
Dr. Thomas J. Hudson
VP of Investor Relations
Ms. Elizabeth Shea
Exec. VP & Chief HR Officer
Mr. Timothy J. Richmond
Exec. VP & Chief Strategy Officer
Mr. Henry O. Gosebruch
Show Less

See Also

Other Stocks